Granted Patent
B2
US 12,622,911 · App. 17/972,963 · Granted May 12, 2026
Methods and compositions for the treatment of pulmonary fibrosis using volasertib
Assignee:
CHILDREN'S HOSPITAL MEDICAL CENTER
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are methods for treating an individual having, or at risk of having, pulmonary fibrosis, wherein volasertib, a salt thereof, or hydrate thereof, is administered to the individual in need thereof. In one aspect, the pulmonary fibrosis may be idiopathic pulmonary fibrosis. The volasertib may be administered in an amount and for a duration of time effective to achieve one or more outcomes selected from decreased invasiveness of pulmonary fibroblasts, increased clearance of myofibroblasts, decreased migration of pulmonary fibroblasts, decreased pulmonary fibroblast proliferation, decreased cell adhesion of pulmonary fibroblasts, decreased myofibroblast activation, decreased extracellular matrix (ECM) accumulation or production, and improved lung function.
Claims (17)
1 . A method for treating an individual for idiopathic pulmonary fibrosis comprising administering volasertib, or a salt thereof, or hydrate thereof.
2 . The method of claim 1 wherein said administering is in an amount and for a duration of time effective to attenuate fibrosis progression associated with pulmonary fibrosis.
3 . The method of claim 1 wherein said administering is in an amount and for a duration of time effective to achieve one or more outcomes selected from decreased invasiveness of pulmonary fibroblasts, increased clearance of myofibroblasts, decreased migration of pulmonary fibroblasts, decreased pulmonary fibroblast proliferation, decreased cell adhesion of pulmonary fibroblasts, decreased myofibroblast activation, decreased extracellular matrix (ECM) accumulation or production, and improved lung function.
4 . The method of claim 1 wherein said administering is in an amount and for a duration of time effective to improve lung function, wherein lung function is measured by one or more of spirometry, pulse oximetry, exercise stress test or arterial blood gas test.
5 . The method of claim 1 , further comprising administering a second agent selected from one or more of nintedanib, pirfenidone, tocilizumab, nivolumab, pembrolizumab, pidilizumab, lambrolizumab, atezolizumab, durvalumab, avelumab, ofnivolumab, and ipilmumab.
6 . The method of claim 5 , wherein said second agent is administered prior to said volasertib administration.
7 . The method of claim 1 , wherein said administration comprises a loading dose and a maintenance dose.
8 . The method of claim 1 , wherein said administration comprises a loading dose and a maintenance dose, wherein said loading dose is larger than said maintenance dose.
9 . The method of claim 1 , wherein said individual is an adult.
10 . The method of claim 1 , wherein said individual is under 18 years of age.
11 . The method of claim 1 , wherein said individual is pre-pubescent.
12 . The method of claim 1 , wherein said administration is selected from one or more of oral, parenteral, intravenous, and subcutaneous.
13 . The method of claim 1 , wherein said administration is via inhalation.
14 . The method of claim 1 , wherein said volasertib is administered at an interval selected from twice a day, three times a day, daily, every other day, every three days, every four days, every five days, every six days, weekly, every two weeks, every three weeks, and monthly.
15 . The method of claim 5 , wherein said second agent is administered simultaneously with said volasertib administration.
16 . The method of claim 5 , wherein said second agent is administered after said volasertib administration.
17 . The method of claim 1 , wherein the administering comprises administering to the individual from 90 mg to 500 mg of volasertib, or a salt thereof, or hydrate thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 6, 2026
From: MADALA, SATISH KUMAR
To: CHILDREN'S HOSPITAL MEDICAL CENTER
Reel/Frame 073995/0033 →
Continuity (2)
Provisional Application
63272256
· Oct 27, 2021
References Cited (310)
US 20110318393A1
· Ladouceur et al.
· 2011
[cited by applicant]
US 20130289014A1
· Solca et al.
· 2013
[cited by applicant]
US 20210213037A1
· Madala et al.
· 2021
[cited by applicant]
CN 104906120A
· 2015
[cited by applicant]
WO 2004058781A1
· 2004
[cited by applicant]
WO 2006036883A2
· 2006
[cited by applicant]
WO 2009073224A1
· 2009
[cited by applicant]
WO 2010009985A2
· 2010
[cited by applicant]
WO 2010056931A1
· 2010
[cited by applicant]
WO 2012021974A1
· 2012
[cited by applicant]
WO 2012034942A1
· 2012
[cited by applicant]
WO 2015069217A1
· 2015
[cited by applicant]
WO 2016103223A1
· 2016
[cited by applicant]
WO 2018086584A1
· 2018
[cited by applicant]
Yu J, et.al. PLK1 Inhibition alleviates transplant-associated obliterative bronchiolitis by suppressing myofibroblast differentiation. Aging (Albany NY). Jun. 15, 2020;12(12):11636-11652. (Year: 2020).
[cited by examiner]
Hu M. et. al. Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis. J Pharmacol Exp Ther. Oct. 2014;351(1):87-95. (Year: 2014).
[cited by examiner]
Karimi-Shah, B., and Chowdhury, B. A. Forced Vital Capacity in Idiopathic Pulmonary Fibrosis—FDA Review of Pirfenidone and Nintedanib. N Engl J Med 2015; 372:1189-1191 (Year: 2015).
[cited by examiner]
Wollin L, et. al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. May 2015;45(5):1434-45. (Year: 2015).
[cited by examiner]
Ottmann, O.G. et. al. Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. Br J Haematol. 2019. 184: 1018-…
[cited by examiner]
Lin, CC. et al. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer 110, 2434-2440 (2014). (Year: 2014).
[cited by examiner]
Doz, F, Locatelli, F, Baruchel, A, et al. Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. Pediatr Blood Cancer. 2019; 66:e27900. (Year: 2019).
[cited by examiner]
Li Y, et. al. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med. Jul. 4, 2011;208(7):1459-71. (Year: 2011).
[cited by examiner]
Cai GQ, et. al. Downregulation of FAK-related non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts. Exp Cell Res. May 15, 2010;316(9):1600-9. (Year: 2010).
[cited by examiner]
Jiang, L., Li, Y., Yu, J. et al. A dry powder inhalable formulation of salvianolic acids for the treatment of pulmonary fibrosis: safety, lung deposition, and pharmacokinetic study. Drug Deliv. and Transl. Res. 11, 1958…
[cited by examiner]
Bandiera, R., et al., “WT1 maintains adrenal-gonadal-primordium (AGP) identity and marks a novel population of AGP-like progenitors within the adult adrenal gland,” Dev Cell, 2013, 27(1):5-18, 27 pgs.
[cited by applicant]
Baughman, R.P., et al., “Overexpression of Transforming Growth Factor-α and Epidermal Growth Factor-receptor in Idiopathic Pulmonary Fibrosis,” Sarcoidosis Vasc Diffuse Lung Dis, 1999, 16:57-61, 5 pgs.
[cited by applicant]
Blackwell, T.S., et al., “Future Directions in Idiopathic Pulmonary Fibrosis Research: An NHLBI Workshop Report,” Am J Respir Crit Care Med, 2014, 189(2):214-222, 9 pgs.
[cited by applicant]
Bogdan, S., et al., “Epidermal growth factor receptor signaling,” Curr Biol, 2001, 11(8):PR292-R295, 4 pgs.
[cited by applicant]
Castriotta, R.J., et al., “Workshop on Idiopathic Pulmonary Fibrosis in Older Adults,” Chest, 2010, 138(3):693-703, 11 pgs.
[cited by applicant]
Chen, G., et al., “Foxa3 Induces Goblet Cell Metaplasia and Inhibits Innate Antiviral Immunity,” Am J Respir Crit Care Med, 2014, 189(3):301-313, 13 pgs.
[cited by applicant]
Chen, H., et al., “Targeting oncogenic Myc as a strategy for cancer treatment,” Signal Transduct Target Ther, 2018, 3:5, 7 pgs.
[cited by applicant]
Chen, J., et al., “ToppGene Suite for gene list enrichment analysis and candidate gene prioritization,” Nucleic Acids Res, 2009, 37:W305-W311, 7 pgs.
[cited by applicant]
Crystal, R.G., et al., “Future Research Directions in Idiopathic Pulmonary Fibrosis: Summary of a National Heart, Lung, and Blood Institute Working Group,” Am J Respir Crit Care Med, 2002, 166:236-246, 11 pgs.
[cited by applicant]
Crystal, R.G., et al., “Interstitial Lung Disease: Current Concepts of Pathogenesis, Staging and Therapy,” Am J Med, 1981, 70:542-568, 27 pgs.
[cited by applicant]
Da Silva, F., et al., “Identifying Direct Downstream Targets: WT1 ChIP-Seq Analysis,” Chapter 15 in Nicolas Hastie (ed.),
[cited by applicant]
De Minicis, S., et al., “Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo,” Gut, 2008, 57(3):352-364, 13 pgs.
[cited by applicant]
Depianto, D.J., et al., “Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis,” Thorax, 2015, 70(1):48-56, 20 pgs.
[cited by applicant]
Ebrahimkhani, M.R., et al., “Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats,” Gut, 2006, 55:1606-1616.
[cited by applicant]
Gajjala, P.R., et al., “Notch 3: A New Culprit in Fibrotic Lung Disease,” Am J Respir Cell Ma Bio, 2021, 64(4):403-404, 2 pgs.
[cited by applicant]
Gebeshuber, C.A., et al., “Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1,” Nat Med, 2013, 19(4):481-487, 9 pgs.
[cited by applicant]
Glasser, S.W., et al., “Mechanisms of Lung Fibrosis Resolution,” Am J Pathol, 2016, 186(5):1066-1077, 12 pgs.
[cited by applicant]
Glienke, W., et al., “Effective treatment of leukemic cell lines with wt1 siRNA,” Leukemia, 2007, 21:2164-2170, 7 pgs.
[cited by applicant]
Haak, A.J., et al., “Matrix Biomechanics and Dynamics in Pulmonary Fibrosis,” Matrix Biol, 2018, 73:64-76, 21 pgs.
[cited by applicant]
Hardie, W.D., et al., “EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-α-induced pulmonary fibrosis,” Am J Physiol Lung Cell Mol Physiol, 2008, 294:L1217-L1225, 9 pgs.
[cited by applicant]
Hardie, W.D., et al., “Reversal of Lung Lesions in Transgenic Transforming Growth Factor α Mice by Expression of Mutant Epidermal Growth Factor Receptor,” Am J Respir Cell Mol Biol, 1996, 15:499-508, 10 pgs.
[cited by applicant]
Hardie, W.D., et al., “Genomic Profile of Matrix and Vasculature Remodeling in TGF-α-Induced Pulmonary Fibrosis,” Am J Respir Cell Mol Biol, 2007, 37:309-321, 13 pgs.
[cited by applicant]
Horowitz, J.C., et al., “Mechanisms for the Resolution of Organ Fibrosis,” Physiology, 2019, 34:43-55, 13 pgs.
[cited by applicant]
Hu, B., et al., “Mesenchymal Deficiency of Notch1 Attenuates Bleomycin-Induced Pulmonary Fibrosis,” Am J Pathol, 2015, 185(11):3066-3075, 10 pgs.
[cited by applicant]
Jorissen, R.N., et al., “Epidermal growth factor receptor: mechanisms of activation and signalling,” Exp Cell Res, 2003, 284:31-53, 23 pgs.
[cited by applicant]
Kasam, R.K., et al., “Fibrocyte accumulation in the lungs of cystic fibrosis patients,” J Cystic Fibrosis, 2020, 19(5):815-822, 8 pgs.
[cited by applicant]
Kasam, R.K., et al., “Inhibition of Aurora Kinase B attenuates fibroblast activation and pulmonary fibrosis,” EMBO Mol Med, 2020, 12:e12131, 16 pgs.
[cited by applicant]
Kasam, R.K., et al., “Dysregulation of Mesenchymal Cell Survival Pathways in Severe Fibrotic Lung Disease: The Effect of Nintedanib Therapy,” Front Pharmacol, 2019, 10:532, 16 pgs.
[cited by applicant]
Korfhagen, T.R., et al., “SAM-pointed domain ETS factor mediates epithelial cell-intrinsic innate immune signaling during airway mucous metaplasia,” PNAS, 2012, 109(41):16630-16635, 6 pgs.
[cited by applicant]
Korfhagen, T.R., et al., “Rapamycin Prevents Transforming Growth Factor-α-Induced Pulmonary Fibrosis,” Am J Respir Cell Mol Biol, 2009, 41:562-572, 11 pgs.
[cited by applicant]
Kramer, E.L., et al., “Subacute TGFβ expression drives inflammation, goblet cell hyperplasia, and pulmonary function abnormalities in mice with effects dependent on CFTR function,” Am J Physiol Lung Cell Mol Physiol, 20…
[cited by applicant]
Kramer, E.L., et al., “Subacute TGFβ Exposure Drives Airway Hyperresponsiveness in Cystic Fibrosis Mice through the PI3K Pathway,” Am J Respir Cell Mol Bio, 2020, 62(5):657-667, 11 pgs.
[cited by applicant]
Luzina, I.G., et al., “Transcriptomic Evidence of Immune Activation in Macroscopically Normal-Appearing and Scarred Lung Tissues in Idiopathic Pulmonary Fibrosis,” Cell Immunol, 2018, 325:1-13, 27 pgs.
[cited by applicant]
Madala, S.K., et al., “Bone Marrow-Derived Stromal Cells Are Invasive and Hyperproliferative and Alter Transforming Growth Factor-α-Induced Pulmonary Fibrosis,” Am J Respir Cell Mol Biol, 2014, 50(4):777-786, 10 pgs.
[cited by applicant]
Madala, S.K., et al., “Dual Targeting of MEK and P13K Pathways Attenuates Established and Progressive Pulmonary Fibrosis,” PloS One, 2014, 9(1):e86536, 11 pgs.
[cited by applicant]
Madala, S.K., et al., “Inhibition of the avß6 integrin leads to limited alteration of TGF-α-induced pulmonary fibrosis,” Am J Physiol Lung Cell Mol Physiol, 2014, 306:L726-L735, 10 pgs.
[cited by applicant]
Madala, S.K., et al., “Matrix Metalloproteinase 12-Deficiency Augments Extracellular Matrix Degrading Metalloproteinases and Attenuates IL-13-Dependent Fibrosis,” J Immunol, 2010, 184(7):3955-3963, 21 pgs.
[cited by applicant]
Madala, S.K., et al., “MEK-ERK Pathway Modulation Ameliorates Pulmonary Fibrosis Associated with Epidermal Growth Factor Receptor Activation,” Am J Respir Cell Mol Biol, 2012, 46(3):380-388, 9 pgs.
[cited by applicant]
Madala, S.K., et al., “p70 ribosomal S6 kinase regulates subpleural fibrosis following transforming growth factor-α expression in the lung,” Am J Physiol Lung Cell Mol Physiol, 2016, 310:L175-L186, 12 pgs.
[cited by applicant]
Madala, S.K., et al., “Resistin-like molecule alphal (Fizz1) recruits lung dendritic cells without causing pulmonary fibrosis,” Respir Res, 2012, 13:51, 10 pgs.
[cited by applicant]
Madala, S.K., et al., “Unique and Redundant Functions of p70 Ribosomal S6 Kinase Isoforms Regulate Mesenchymal Cell Proliferation and Migration in Pulmonary Fibrosis,” Am J Respir Cell Mol Biol, 2016, 55(6):792-803, 12 …
[cited by applicant]
Marlton, P., “The many facets of WT1 in acute myeloid leukemia: clarity remains elusive,” Leukemia & Lymphoma, 2014, 55(2):235-237, 3 pgs.
[cited by applicant]
Mckleroy, W., et al., “Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis,” Am J Physiol Lung Cell Mol Physiol, 2013, 304:L709-L721, 13 pgs.
[cited by applicant]
Moens, C.B., et al., “Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus,” Development, 1993, 119:485-499, 15 pgs.
[cited by applicant]
Noble, P.W., et al., “Pulmonary fibrosis: patterns and perpetrators,” J Clin Invest, 2012, 122(8):2756-2762, 7 pgs.
[cited by applicant]
Okubo, T., et al., “Nmyc plays an essential role during lung development as a dosage-sensitive regulator of progenitor cell proliferation and differentiation,” Development, 2005, 132:1363-1374, 12 pgs.
[cited by applicant]
Que, J., et al., “Mesothelium contributes to vascular smooth muscle and mesenchyme during lung development,” PNAS, 2008, 105(43):16626-16630, 5 pgs.
[cited by applicant]
Reddy, V.S., et al., “Extracellular small heat shock proteins: exosomal biogenesis and function,” Cell Stress and Chaperones, 2018, 23(3):441-454, 14 pgs.
[cited by applicant]
Redente, E.F., et al., “Persistent, Progressive Pulmonary Fibrosis and Epithelial Remodeling in Mice,” Am J Respir Cell Mol Biol, 2021, 64(6):669-676, 8 pgs.
[cited by applicant]
Reyfman, P.A., et al., “Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis,” Am J Respir Crit Care Med, 2019, 199(12):1517-1536, 20 pgs.
[cited by applicant]
Richeldi, L., et al., “Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis,” New Engl J Med, 2014, 370(22):2071-2082, 12 pgs.
[cited by applicant]
Rong, Y., et al., “Wilms' Tumor 1 and Signal Transducers and Activators of Transcription 3 Synergistically Promote Cell Proliferation: A Possible Mechanism in Sporadic Wilms' Tumor,” Cancer Res, 2006, 66(16):8049-8057, …
[cited by applicant]
Rothaeusler, K., et al., “Assessment of Cell Proliferation by 5-Bromodeoxyuridine (BrdU) Labeling for Multicolor Flow Cytometry,” Curr Protoc Cytom, 2007, 7.31.1-7.31.13, 13 pgs.
[cited by applicant]
Ruiz-Perez, M.V., et al., “The MYCN Protein in Health and Disease,” Genes, 2017, 8:113, 27 pgs.
[cited by applicant]
Sawai, S., et al., “Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse,” Development, 1993, 117:1445-1455, 11 pgs.
[cited by applicant]
Selman, M., et al., “Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy,” Ann Intern Med, 2001, 134:136-151, 16 pgs.
[cited by applicant]
Selman, M., et al., “Idiopathic pulmonary fibrosis: misunderstandings between epithelial cells and fibroblasts?” Sarcoidosis Vasc Diffuse Lung Dis, 2004, 21:165-172, 8 pgs.
[cited by applicant]
Singh, B., et al., “Repetitive intradermal bleomycin injections evokes T-helper cell 2 cytokine-driven pulmonary fibrosis,” Am J Physiol Lung Cell Mol Physiol, 2017, 313(5):L796-L806, 11 pgs.
[cited by applicant]
Sontake, V., et al., “New therapeutics based on emerging concepts in pulmonary fibrosis,” Expert Opin Ther Targets, 2019, 23(1):69-81, 25 pgs.
[cited by applicant]
Sontake, V., et al., “Wilms' tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease,” JCI Insight, 2018, 3(16):e121252, 19 pgs.
[cited by applicant]
Sontake, V., et al., “Fibrocytes Regulate Wilms' Tumor 1-Positive Cell Accumulation in Severe Fibrotic Lung Disease,” J Immunol, 2015, 195(8):3978-3991, 32 pgs.
[cited by applicant]
Sontake, V., et al., “Hsp90 regulation of fibroblast activation in pulmonary fibrosis,” JCI Insight, 2017, 2(4):e91454, 19 pgs.
[cited by applicant]
Tsukui, T., et al., “Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis,” Nature Comms, 2020, 11:1920, 16 pgs.
[cited by applicant]
Vicent, S., et al., “Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models,” J Clin Invest, 2010, 120(11):3940-3952, 13 pgs.
[cited by applicant]
Von Gise, A., et al., “Contribution of Fetal, but Not Adult, Pulmonary Mesothelium to Mesenchymal Lineages in Lung Homeostasis and Fibrosis,” Am J Respir Cell Mol Biol, 2016, 54(2):222-230, 9 pgs.
[cited by applicant]
Wang, Y., et al., “Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis,” Ther Adv Respir Dis, 2020, 14:1-17, 17 pgs.
[cited by applicant]
Wang, Y., et al., “Unsupervised gene expression analyses identify IPF-severity correlated signatures, associated genes and biomarkers,” BMC Pulmonary Medicine, 2017, 17(1):133, 10 pgs.
[cited by applicant]
Williams, R.M., et al., “Interpreting Second-Harmonic Generation Images of Collagen I Fibrils,” Biophys J, 2005, 88:1377-1386, 10 pgs.
[cited by applicant]
Wollin, L., et al., “Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis,” Eur Respir J, 2015, 45:1434-1445, 12 pgs.
[cited by applicant]
Xiao, D., et al., “Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival,” Molecular Cell, 2016, 64:493-506, 15 pgs.
[cited by applicant]
Yang, X., et al., “Reversal of myofibroblast differentiation: A review,” Euro J Pharma, 2014, 734:83-90, 8 pgs.
[cited by applicant]
Yombo, D.J.K., et al., “Heat shock protein 70 is a positive regulator of airway inflammation and goblet cell hyperplasia in a mouse model of allergic airway inflammation,” J Biol Chem, 2019, 294(41):15082-15094, 13 pgs.
[cited by applicant]
Yombo, D.J.K., et al., “The Protective Effects of IL-31RA Deficiency During Bleomycin-Induced Pulmonary Fibrosis,” Front Immunol, 2021, 12:645717, 10 pgs.
[cited by applicant]
Zhou, Y., et al., “Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis,” J Clin Invest, 2013, 123(3):1096-1108, 13 pgs.
[cited by applicant]
Zoz, D.F., et al., “Idiopathic Pulmonary Fibrosis: A Disorder of Epithelial Cell Dysfunction,” Am J Med Sci, 2011, 341(6):435-438, 9 pgs.
[cited by applicant]
U.S. Appl. No. 62/630,866, filed Feb. 15, 2018, by: Madala et al., entitled: “Repurposing Barasertib for the Treatment Pulmonary Fibrosis.”
[cited by applicant]
U.S. Appl. No. 63/272,256, filed Oct. 27, 2021, by Madala et al., entitled: “Therapeutic Inhibition of the WT1-MYCN-PLK1 Axis and Pulmonary Fibrosis Using Volasertib.”
[cited by applicant]
Wen et al. (2015) “Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition” Nature Medicine, vol. 21, No. 12, pp. 1473-1480 (plus online methods).
[cited by applicant]
White et al. (2013) “Inflammation, wound repair, and fibrosis: Reassessing the spectrum of tissue injury and resolution” J Pathol, vol. 229, No. 2, 141-144.
[cited by applicant]
Woo et al. (2015) “Elucidating Compound Mechanism of Action by Network Perturbation Analysis” Cell, vol. 162, No. 2, pp. 441-451.
[cited by applicant]
Wynn (2008) “Cellular and molecular mechanisms of fibrosis” J Pathol, vol. 214, No. 2, pp. 199-210.
[cited by applicant]
Wynn et al. (2011) “Quantitative assessment of macrophage functions in repair and fibrosis” Curr Protoc Immunol, Chapter 14:Unit14.22 (15 pages).
[cited by applicant]
Wynn et al. (2012) “Mechanisms of fibrosis: therapeutic translation for fibrotic disease” Nat Med, vol. 18, No. 7, pp. 1028-1040.
[cited by applicant]
Xia et al. (2004) “Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signalin…
[cited by applicant]
Yang et al. (2014) “Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation” Oncotarget, vol. 5, No. 10, pp. 2947-2961.
[cited by applicant]
Zhang et al. (2001) “Vanadium stimulates human bronchial epithelial cells to produce heparin-binding epidermal growth factor-like growth factor: a mitogen for lung fibroblasts” Am J Respir Cell Mol Biol, vol. 24, pp. 12…
[cited by applicant]
Zhang et al. (2018) “Cystic fibrosis transmembrane conductance regulator—emerging regulator of cancer” Cellular and Molecular Life Sciences, vol. 75, pp. 1737-1756.
[cited by applicant]
Zhou et al. (2012) “Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-beta-induced pulmonary fibrosis” J Biol Chem, vol. 287, No. 50, pp.…
[cited by applicant]
Raghu et al. (2006) “Incidence and prevalence of idiopathic pulmonary fibrosis” Am J Respir Crit Care Med, vol. 174, pp. 810-816.
[cited by applicant]
Raghu et al. (2011) “An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management” Am J Respir Crit Care Med, vol. 183, pp. 788-824.
[cited by applicant]
Ramachandran et al. (2014) “A genomic signature approach to rescue DeltaF508-cystic fibrosis transmembrane conductance regulator biosynthesis and function” Am J Respir Cell Mol Biol, vol. 51, pp. 354-362.
[cited by applicant]
Ramalingam et al. (2008) “Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain” Nat Immunol, vol. 9, No. 1, pp. 25-33.
[cited by applicant]
Ramsey et al. (1999) “Intermittent administration of inhaled tobramycin in patients with cystic fibrosis” N Engl J Med, vol. 340, pp. 23-30.
[cited by applicant]
Ratjen et al. (2002) “Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha” Thorax, vol. 57, pp. 930-934.
[cited by applicant]
Ratjen et al. (2012) “Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa” Chest, vol. 142, pp. 1259-1266.
[cited by applicant]
Reddy et al. (2015) “Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer” Invest New Drugs, vol. 33, pp. 977-984.
[cited by applicant]
Retsch-Bogart et al. (2009) “Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis” Chest, vol. 135, pp. 1223-1232.
[cited by applicant]
Rimessi et al. (2015) “Mitochondrial Ca2+-dependent NLRP3 activation exacerbates the Pseudomonas aeruginosa—driven inflammatory response in cystic fibrosis” Nat Commun, vol. 6, Article 6201 (16 pages).
[cited by applicant]
Ritchie et al. (2015) “limma powers differential expression analyses for RNA-sequencing and microarray studies” Nucleic Acids Res, vol. 43, No. 7, Article e47 (13 pages).
[cited by applicant]
Rowe et al. (2013) “Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation” PLoS One, vol. 8, No. 7, Article e66955 (8 pages).
[cited by applicant]
Rowe et al. (2014) “Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis” Am J Respir Grit Care Med, vol. 190, pp. 175-184.
[cited by applicant]
Sagel et al. (2005) “Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis” Pediatr Pulmonol, vol. 39, pp. 224-232.
[cited by applicant]
Sali et al. (1993) “Comparative protein modelling by satisfaction of spatial restraints” J Mol Biol, vol. 234, pp. 779-815.
[cited by applicant]
Schneider et al. (2012) “Pleuropulmonary pathology in patients with rheumatic disease” Arch Pathol Lab Med, vol. 136, pp. 1242-1252.
[cited by applicant]
Shannon et al. (2003) “Cytoscape: a software environment for integrated models of biomolecular interaction networks” Genome Res, vol. 13, pp. 2498-2504.
[cited by applicant]
Sini et al. (2016) “Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases” Mol Cancer Ther; vol. 15, No. 10, pp. 2388-2398 & Supplementary Figure S1.
[cited by applicant]
Sirota et al. (2011) “Discovery and preclinical validation of drug indications using compendia of public gene expression data” Sci Transl Med, vol. 3, Article 96ra77 (22 pages).
[cited by applicant]
Solomon et al. (2010) “An international randomized multicenter comparison of nasal potential difference techniques” Chest, vol. 138, pp. 919-928.
[cited by applicant]
Spagnola et al. (2017) “Clinical trial research in focus: why do so many clinical trials fail in IPF?” Lancet Respir Med, vol. 5, No. 5, pp. 372-374.
[cited by applicant]
Srikumar et al. (2016) “Potential Use of Flavopiridol in Treatment of Chronic Diseases” from Advances in Ex. Med. & Bio. Vol. 929, Drug Discovery from Mother Nature, Edited by Gupta et al. (Copyright 2016) Springer, Cha…
[cited by applicant]
Stahlman et al. (1989) “Immunocytochemical localization of epidermal growth factor in the developing human respiratory system and in acute and chronic lung disease in the neonate” Lab Invest, vol. 60, No. 4, pp. 539-547.
[cited by applicant]
Stanke et al. (2014) “The CF-modifying gene EHF promotes p.Phe508del-CFTR residual function by altering protein glycosylation and trafficking in epithelial cells” European journal of human genetics, vol. 22, pp. 660-666.
[cited by applicant]
Stanton (2017) “Effects of Pseudomonas aeruginosa on CFTR chloride secretion and the host immune response” Am J Physiol Cell Physiol, vol. 312, pp. C357-C366.
[cited by applicant]
Steele et al. (2013) “Molecular mechanisms in progressive idiopathic pulmonary fibrosis” Annu Rev Med, vol. 64, pp. 265-276.
[cited by applicant]
Stoltz et al. (2010) “Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth” Sci Transl Med, vol. 2, Article 29ra31 (18 pages).
[cited by applicant]
Strandjord et al. (1995) “Immunolocalization of transforming growth factor-alpha, epidermal growth factor (EGF), and EGF-receptor in normal and injured developing human lung” Pediatr Res, vol. 38, No. 6, pp. 851-856.
[cited by applicant]
Subramanian et al. (2017) “A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles” Cell, vol. 171, No. 6, pp. 1437-1452.e17.
[cited by applicant]
Sun et al. (2011) “New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis” Am J Physiol Lung Cell Mol Physiol, vol. 300, pp. L341-L353.
[cited by applicant]
Sun et al. (2022) “90% of drugs fail clinical trials - here's one way researchers can select better drug candidates” in The Conversation at https://theconversation.com/90-of-drugs-fail-clinical-trials-heres-one-way-rese…
[cited by applicant]
Sundberg et al. (2014) “Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells” Proc Natl Acad Sci U S A, vol. 111, No…
[cited by applicant]
Swigris et al. (2011) “Benefits of Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis” Resp. Care, vol. 56, No. 6, pp. 783-789.
[cited by applicant]
Thannickal et al. (2004) “Mechanisms of pulmonary fibrosis” Annu Rev Med, vol. 55, pp. 395-417.
[cited by applicant]
Trepel et al. (2010) “Targeting the dynamic HSP90 complex in cancer” Nat Rev Cancer, vol. 10, No. 8, pp. 537-549.
[cited by applicant]
Trzcinska-Daneluti et al. (2012) “Use of Kinase Inhibitors to Correct delta-F508-CFTR Function” Molecular & Cellular Proteomics 11.9, pp. 745-757. (plus supplemental material).
[cited by applicant]
Tyler et al. (2007) “VX-680 inhibits Aurora A and Aurora B kinase activity in human cells” Cell Cycle, vol. 6, No. 22, pp. 2846-2854.
[cited by applicant]
Varisco et al. (2016) “Excessive Reversal of Epidermal Growth Factor Receptor and Ephrin Signaling Following Tracheal Occlusion in Rabbit Model of Congenital Diaphragmatic Hernia” Mol Med, vol. 22, pp. 398-411.
[cited by applicant]
Varone et al. (2017) “Investigational drugs for idiopathic pulmonary fibrosis” Expert Opinion on Investigational Drugs, vol. 26, No. 9, pp. 1019-1031.
[cited by applicant]
Veit et al. (2014) “Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression” Science translational medicine, vol. 6, No. 246, Article 246ra97 (33 pages).
[cited by applicant]
Verleden et al. (2017) “Chronic lung allograft dysfunction phenotypes and treatment” J Thorac Dis, vol. 9, No. 8, pp. 2650-2659.
[cited by applicant]
Vermeer et al. (2003) “Segregation of receptor and ligand regulates activation of epithelial growth factor receptor” Nature, vol. 422, pp. 322-326.
[cited by applicant]
Vertex Pharmaceuticals Inc. (2011) “Vertex and Cystic Fibrosis Foundation Therapeutics to Collaborate on Discovery and Development of New Medicines to Treat the Underlying Cause of Cystic Fibrosis” online at https://inv…
[cited by applicant]
Vertex Pharmaceuticals Inc. (2016) “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor” oncline at: https://clinicaltrials.go…
[cited by applicant]
Wainwright et al. (2015) “Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR” N Engl J Med, vol. 373, pp. 220-231.
[cited by applicant]
Wang et al. (2003) “Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus” Nature, vol. 424, pp. 456-461.
[cited by applicant]
Wang et al. (2010) “STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer” Current Opinion in Investigational Drugs, vol. 11, No. 12, pp. 1466-1476.
[cited by applicant]
Wang et al. (2018) “PP-2, a src-kinase inhibitor, is a potential corrector for F508del-CFTR in cystic fibrosis” bioRxiv 288324; doi: https://doi.org/10.1101/288324 (42 pages).
[cited by applicant]
Kannan et al. (2006) “Src kinase Lyn is crucial for Pseudomonas aeruginosa internalization into lung cells” Eur J Immunol, vol. 36, pp. 1739-1752.
[cited by applicant]
Kaufman et al. (2015) “Fyn inhibition rescues established memory and synapse loss in Alzheimer mice” Ann Neural, vol. 77, pp. 953-971.
[cited by applicant]
Kim et al. (2016) “PubChem Substance and Compound databases” Nucleic Acids Res, vol. 44, pp. D1202-D1213.
[cited by applicant]
Kleaveland et al. (2014) “Fibrocytes are not an essential source of type I collagen during lung fibrosis” J Immunol, vol. 193, No. 10, pp. 5229-5239.
[cited by applicant]
Kopeikin et al. (2014) “Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels” Journal of Cystic Fibrosis, vol. 13, pp. 508-514.
[cited by applicant]
Kubiak et al. (1992) “Transforming growth factor-alpha gene expression in late-gestation fetal rat lung” Pediatr Res, vol. 31, No. 3, pp. 286-290.
[cited by applicant]
Lamb (2007) “The Connectivity Map: a new tool for biomedical research” Nat Rev Cancer, vol. 7, pp. 54-60.
[cited by applicant]
Lamb et al.(2006) “The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease” Science, vol. 313, pp. 1929-1935.
[cited by applicant]
Law et al. (2014) “voom: Precision weights unlock linear model analysis tools for RNA-seq read counts” Genome Biol, vol. 15, Article R29 (17 pages).
[cited by applicant]
Le et al. (2014) “Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis” J Immunol, vol. 193, pp. 3755-3768.
[cited by applicant]
Lemjabbar et al. (2003) “Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin” J Biol Chem, vol. 278, No. 28, pp. 26202-26207.
[cited by applicant]
Lepanto et al. (2011) “Pseudomonas aeruginosa interacts with epithelial cells rapidly forming aggregates that are internalized by a Lyn-dependent mechanism” Cell Microbiol, vol. 13, pp. 1212-1222.
[cited by applicant]
Li et al. (2005) “Lysophosphatidic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions” J Exp Med, vol. 202, pp. 975-986.
[cited by applicant]
Li et al. (2007) “Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia” Cell, vol. 131, pp. 940-951.
[cited by applicant]
Liu et al. (2016) “Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases” J Exp Clin Cancer Res., vol. 35, Article 183 (15 pages).
[cited by applicant]
Lukacs et al. (2012) “CFTR: folding, misfolding and correcting the ˜F508 conformational defect” Trends Mol Med, vol. 18, No. 2, pp. 81-91.
[cited by applicant]
Madtes et al. (1988) “Induction of transforming growth factor-alpha in activated human alveolar macrophages” Cell, vol. 53, pp. 285-293.
[cited by applicant]
Madtes et al. (1998) “Elevated transforming growth factor-alpha levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome” Am J Respir Crit Care Med, vol. 158, No. 2, pp. 424-430.
[cited by applicant]
Maisonneuve et al. (2013) “Cancer Risk in Cystic Fibrosis: A 20-Year Nationwide Study From the United States” J Natl Cancer Inst, vol. 105, pp. 122-129.
[cited by applicant]
Marshall et al. (2024) “The case of the missing mouse-developing cystic fibrosis drugs without using animals” Front Drug Discov, vol. 4, Article 1347246 (7 pages).
[cited by applicant]
Mitra et al. (2005) “Focal adhesion kinase: in command and control of cell motility” Nat Rev Mol Cell Biol, vol. 6, pp. 56-68.
[cited by applicant]
Moon et al. (2015) “Compartmentalized accumulation of cAMP near complexes of multidrug resistance protein 4 (MRP4) and cystic fibrosis transmembrane conductance regulator (CFTR) contributes to drug-induced diarrhea.” J …
[cited by applicant]
Moore et al. (2005) CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol, vol. 166, No. 3, pp. 675-684.
[cited by applicant]
Moore et al. (2013) “Animal models of fibrotic lung disease” Am J Respir Cell Mol Biol, vol. 49, No. 2, pp. 167-179.
[cited by applicant]
Morris et al. (2009) “AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility” J Comput Chem, vol. 30, pp. 2785-2791.
[cited by applicant]
Muhlebach et al. (2016) “Biomarkers for cystic fibrosis drug development” J Cyst Fibros, vol. 15, pp. 714-723.
[cited by applicant]
Nichols et al. (2008) “Anti-inflammatory therapies for cystic fibrosis-related lung disease” Clin Rev Allergy Immunol, vol. 35, pp. 135-153.
[cited by applicant]
Nichols et al. (2015) “Inflammation and its genesis in cystic fibrosis” Pediatr Pulmonol, vol. 50, pp. S39-S56.
[cited by applicant]
Nygaard et al. (2014) “Fyn kinase inhibition as a novel therapy for Alzheimer's disease” Alzheimers Res Ther, vol. 6, Article 8 (8 pages).
[cited by applicant]
Nygaard et al. (2015) “A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease” Alzheimer's Research & Therapy, vol. …
[cited by applicant]
Oermann et al. (2011) “Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI)” J Antimicrob Chemother, vol. 66, pp. 2398-2404.
[cited by applicant]
Ogilvie et al. (2011) “Differential global gene expression in cystic fibrosis nasal and bronchial epithelium” Genomics, vol. 98, pp. 327-336.
[cited by applicant]
Olson et al. (2007) “Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003” Am J Respir Crit Care Med, vol. 176, pp. 277-284.
[cited by applicant]
O'Neal et al. (2015) “Gene expression in transformed lymphocytes reveals variation in endomembrane and HLA pathways modifying cystic fibrosis pulmonary phenotypes” Am J Hum Genet, vol. 96, pp. 318-328.
[cited by applicant]
Ooms (2014) “The jsonlite Package: A Practical and Consistent Mapping Between JSON Data and R Objects” In arXiv e-prints at arXiv:403.2805 (29 pages).
[cited by applicant]
O'Sullivan et al. (2011) “Health care utilization & costs for cystic fibrosis patients with pulmonary infections” Manag Care, vol. 20, pp. 37-44.
[cited by applicant]
Panicker et al. (2015) “Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease” J Neurosci, vol. 35, pp. 10058-10077.
[cited by applicant]
Pankow et al. (2015) “F508 Cftr interactome remodelling promotes rescue of cystic fibrosis” Nature, vol. 528, pp. 510-516.
[cited by applicant]
Park et al. (2015) “Pathophysiological changes induced by Pseudomonas aeruginosa infection are involved in MMP-12 and MMP-13 upregulation in human carcinoma epithelial cells and a pneumonia mouse model” Infect Immun, vo…
[cited by applicant]
Park et al. (2016) “Type III Secretion System of Pseudomonas aeruginosa Affects Matrix Metalloproteinase 12 (MMP-12) and MMP-13 Expression via Nuclear Factor kB Signaling in Human Carcinoma Epithelial Cells and a Pneumo…
[cited by applicant]
Peschon et al. (1998) “An essential role for ectodomain shedding in mammalian development” Science, vol. 282, No. 5392, pp. 1281-1284.
[cited by applicant]
Phuan et al. (2015) “Potentiators of Defective DeltaF508-CFTR Gating that Do Not Interfere with Corrector Action” Mol Pharmacol, vol. 88, pp. 791-799.
[cited by applicant]
Pillai et al. (2014) “Heat shock protein 90 inhibitors in non-small-cell lung cancer” Curr Opin Oncol, vol. 26, No. 2, pp. 159-164.
[cited by applicant]
Polosa et al. (1999) “Expression of c-erbB receptors and ligands in human bronchial mucosa” Am J Respir Cell Mol Biol, vol. 20, pp. 914-923.
[cited by applicant]
Polosukhin et al. (2012) “Intratracheal bleomycin causes airway remodeling and airflow obstruction in mice” Exp Lung Res, vol. 38, No. 3, pp. 135-146.
[cited by applicant]
Qu et al. (2009) “Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships” BMC Bioinformatics, vol. 10, Suppl 5, Article S4 (16 pages).
[cited by applicant]
Qu et al. (2012) “Applications of Connectivity Map in drug discovery and development” Drug Discov Today, vol. 17, pp. 1289-1298.
[cited by applicant]
Qu et al. (2014) “Integrative clinical transcriptomics analyses for new therapeutic intervention strategies: a psoriasis case study” Drug Discov Today, vol. 19, pp. 1364-1371.
[cited by applicant]
Dammann et al. (2003) “Role of neuregulin-1 beta in the developing lung” Am J Respir Crit Care Med, vol. 167, pp. 1711-1716.
[cited by applicant]
Dar et al. (2010) “Aurora Kinase Inhibitors—Rising Stars in Cancer Therapeutics?” Mol Cancer Ther, vol. 9, No. 2, pp. 268-278.
[cited by applicant]
De Santis et al. (2014) “Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab” Oncotarget, vol. 5, No. 19, pp. 9239-9255.
[cited by applicant]
Dekkers et al. (2013) “A functional CFTR assay using primary cystic fibrosis intestinal organoids” Nature Medicine, vol. 19, pp. 939-945.
[cited by applicant]
Dekkers et al. (2013) “Novel opportunities for CFTR-targeting drug development using organoids” Rare Dis, vol. 1, No. 1, Article e27112 (6 pages).
[cited by applicant]
Dekkers et al. (2016) “Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis” Sci Transl Med, vol. 8, No. 344, Article 344ra84 (12 pages).
[cited by applicant]
Dudley et al. (2011) “Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease” Sci Transl Med, vol. 3, No. 96, Article 96ra76 (12 pages).
[cited by applicant]
Dunkelberger et al. (2010) “Complement and its role in innate and adaptive immune responses” Cell Res, vol. 20, pp. 34-50.
[cited by applicant]
Elizur et al. (2008) “Airway inflammation in cystic fibrosis” Chest, vol. 133, pp. 489-495.
[cited by applicant]
Eschenbrenner et al. (2013) “Role of JAK-STAT pathway in pulmonary fibrosis” Pneumologie, vol. 67, Article P06 (1 page).
[cited by applicant]
Esen et al. (2001) “Invasion of human epithelial cells by Pseudomonas aeruginosa involves src-like tyrosine kinases p60Src and p59Fyn” Infect Immun, vol. 69, pp. 281-287.
[cited by applicant]
Fancelli et al. (2006) “1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile” J. Med. Chem., vol. 49, No. 24, pp. 7247-7251.
[cited by applicant]
Fernandes et al. (1999) “Production of epidermal growth factor related ligands in tumorigenic and benign human lung epithelial cells” Cancer Lett, vol. 142, pp. 55-63.
[cited by applicant]
Fiorotto et al. (2016) “The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity” Hepatology, vol. 64, No. 6 , pp. 2118…
[cited by applicant]
Fiorotto et al. (2018) “Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves CFTR correctors efficacy” Hepatology, vol. 67, No. 3, pp. 972-988.
[cited by applicant]
Floc'h et al. (2017) “Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles” Mol Cancer Ther, vol. 16, No. 6, pp. 1031-1040.
[cited by applicant]
Gaggar et al. (2007) “Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients” Am J Physiol Lung Cell Mol Physiol, vol. 293, pp. L96-L104.
[cited by applicant]
Gaggar et al. (2011) “The role of matrix metalloproteinases in cystic fibrosis lung disease” Eur Respir J, vol. 38, pp. 721-727.
[cited by applicant]
Gajjala et al. (2023) “Wilms Tumor 1-Driven Fibroblast Activation and Subpleural Thickening in Idiopathic Pulmonary Fibrosis” Int J Mol Sci, vol. 24, Article 2850 (13 pages).
[cited by applicant]
Gallucci et al. (2000) “TNF-alpha regulates transforming growth factor-alpha expression in regenerating murine liver and isolated hepatocytes” J Immunol, vol. 164, pp. 872-878.
[cited by applicant]
Godl et al. (2005) “Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling” Cancer Res., vol. 65, No. 15 pp. 6919-6926.
[cited by applicant]
Goldenson et al. (2015) “The aurora kinases in cell cycle and leukemia” Oncogene, vol. 34, No. 5, pp. 537-545.
[cited by applicant]
Greene et al. (2015) “Understanding multicellular function and disease with human tissue-specific networks” Nat Genet, vol. 47, No. 6, pp. 569-576.
[cited by applicant]
Gubens et al. (2015) “A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies” Lung Cancer, vol. 89, No. 1, pp. 57-60.
[cited by applicant]
Guo et al. (2014) “CD24 activates the NLRP3 inflammasome through c-Src kinase activity in a model of the lining epithelium of inflamed periodontal tissues” Immun Inflamm Dis, vol. 2, pp. 239-253.
[cited by applicant]
Hamada et al. (2005) “Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice” J Immunol, vol. 175, pp. 1224-1231.
[cited by applicant]
Hannon et al. (2010) “Effects of the Src Kinase Inhibitor Saracatinib (AZD0530) on Bone Turnover in Healthy Men: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending-Dose Phase I Trial” Journal of Bone and…
[cited by applicant]
Hannon et al. (2012) “Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study” Bone, vol. 50, No. 4, pp. 885-892.
[cited by applicant]
Hardie et al. (1999) “Immunolocalization of transforming growth factor alpha and epidermal growth factor receptor in lungs of patients with cystic fibrosis” Pediatr Dev Pathol,, vol. 2, No. 5, pp. 415-423.
[cited by applicant]
Hardie et al. (2004) “Conditional expression of transforming growth factor-alpha in adult mouse lung causes pulmonary fibrosis” Am J Physiol Lung Cell Mol Physiol, vol. 286, pp. L741-L749.
[cited by applicant]
Hardie et al. (2010) “Signaling pathways in the epithelial origins of pulmonary fibrosis” Cell Cycle, vol. 9, No. 14, pp. 2769-2776.
[cited by applicant]
Hecht (2000) “Bleomycin: new perspectives on the mechanism of action” J Nat Prod, vol. 63, pp. 158-168.
[cited by applicant]
Helfrich et al. (2016) “Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo” Mol Cancer Ther, vol. 15, No. 10, pp. 2314-2322.
[cited by applicant]
Hennequin et al. (2006) N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H- pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kin…
[cited by applicant]
Hou et al (2016) “Emerging role of cystic fibrosis transmembrane conductance regulator—an epithelial chloride channel in gastrointestinal cancers” World J Gastrointest Oncol, vol. 8, No. 3, pp. 282-288.
[cited by applicant]
Howard et al. (2009) “Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity” J Med Chem, vol. 52, No. 2, pp. 379-388.
[cited by applicant]
Hoyle et al. (1999) “Emphysematous lesions, inflammation, and fibrosis in the lungs of transgenic mice overexpressing platelet-derived growth factor” Am J Pathol, vol. 154, No. 6, pp. 1763-1775.
[cited by applicant]
Hu et al. (2009) “Human disease-drug network based on genomic expression profiles” PLoS One, vol. 4, No. 8, Article e6536 (11 pages).
[cited by applicant]
Hutchison et al. (2013) “Resident mesenchymal cells and fibrosis” Biochim Biophys Acta, vol. 1832, No. 7, pp. 962-971.
[cited by applicant]
Tannitti et al. (2016) “IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis” Nat Commun, vol. 7, Article 10791 (16 pages).
[cited by applicant]
Ibrahim et al. (2015) “Inhalation drug delivery devices: technology update” Medical Devices: Evidence and Research, vol. 8, pp. 131-139.
[cited by applicant]
Inoue et al. (2002) “Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis” Am J Respir Crit Care Med, vol. 166, pp. 765-773.
[cited by applicant]
Torio et al. (2010) “Discovery of drug mode of action and drug repositioning from transcriptional responses” Proc Natl Acad Sci U S A, vol. 107, pp. 14621-14626.
[cited by applicant]
Torio et al. (2010) “Identification of small molecules enhancing autophagic function from drug network analysis” Autophagy, vol. 6, pp. 1204-1205.
[cited by applicant]
Jakubzick et al. (2004) “Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia” J Clin Pathol, vol. 57, pp. 477-486.
[cited by applicant]
Jenkins et al. (2017) “An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis” Am J Respir Cell Mol Biol, vol. 56, No. 5,…
[cited by applicant]
Jetton et al. (2009) “The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms” Molecular Microbiology, vol. 72, No. 2 pp…
[cited by applicant]
CN104906120A English-language translation, 2015 (12 pages).
[cited by applicant]
International Search Report from PCT/US2019/017917, mailed May 15, 2019, 3 pages.
[cited by applicant]
Written Opinion from PCT/US2019/017917, mailed May 15, 2019, 4 pages.
[cited by applicant]
International Search Report from PCT/US2018/033780, mailed Aug. 7, 2018, 3 pages.
[cited by applicant]
Written Opinion from PCT/US2018/033780, mailed Aug. 7, 2018, 5 pages.
[cited by applicant]
Restriction Requirement in U.S. Appl. No. 16/614,356 dated Jun. 1, 2021, 8 pages.
[cited by applicant]
Response to Restriction Requirement in U.S. Appl. No. 16/614,356 dated Jul. 23, 2021, 5 pages.
[cited by applicant]
Non final Office action in U.S. Appl. No. 16/614,356 dated Aug. 18, 2021, 30 pages.
[cited by applicant]
Restriction Requirement in U.S. Appl. No. 16/967,441 dated Dec. 22, 2021, 9 pages.
[cited by applicant]
Response to Restriction Requirement in U.S. Appl. No. 16/967,441 dated Feb. 21, 2022, 4 pages.
[cited by applicant]
NonFinal Office action in U.S. Appl. No. 16/967,441 dated Apr. 18, 2022, 44 pages.
[cited by applicant]
Response to non final Office action in U.S. Appl. No. 16/967,441 dated Jul. 27, 2022, 21 pages.
[cited by applicant]
Final Office Action in U.S. Appl. No. 16/967,441 dated Oct. 20, 2022, 25 pages.
[cited by applicant]
Request for Continued Examination and Response to Final Office action in U.S. Appl. No. 16/967,441 dated Jan. 15, 2023, 15 pages.
[cited by applicant]
NonFinal Office action in U.S. Appl. No. 16/967,441 dated Apr. 3, 2023, 15 pages.
[cited by applicant]
Response to non final Office action in U.S. Appl. No. 16/967,441 dated Jun. 22, 2023, 20 pages.
[cited by applicant]
Final Office action in U.S. Appl. No. 16/967,441 dated Aug. 22, 2023, 15 pages.
[cited by applicant]
Request for Continued Examination and Response to Final Office action in U.S. Appl. No. 16/967,441 dated Feb. 16, 2024, 20 pages.
[cited by applicant]
Nonfinal Office action in U.S. Appl. No. 16/967,441 dated Jun. 27, 2024, 19 pages.
[cited by applicant]
Response to non final Office action in U.S. Appl. No. 16/967,441 dated Sep. 8, 2024, 20 pages.
[cited by applicant]
Final Office action in U.S. Appl. No. 16/967,441 dated Oct. 11, 2024, 11 pages.
[cited by applicant]
Request for Continued Examination and Response to Final Office action in U.S. Appl. No. 16/967,441 dated Dec. 31, 2024,18 pages.
[cited by applicant]
Nonfinal Office action in U.S. Appl. No. 17/650,846 dated Sep. 11, 2024, 41 pages.
[cited by applicant]
Response to Nonfinal Office action in U.S. Appl. No. 17/650,846 dated Jan. 21, 2025, 18 pages.
[cited by applicant]
Abraham et al. (2017) “Cystic Fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer” Journal of Cystic Fibrosis, vol. 16, pp. S40-S49.
[cited by applicant]
Accurso et al. (2010) “Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation” N Engl J Med, vol. 363, pp. 1991-2003.
[cited by applicant]
Ahluwalia et al. (2014) “New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses” Am J Respir Crit Care Med, vol. 190, No. 8, pp. 867-878.
[cited by applicant]
Ahmad et al. (2009) “Exhaled nitric oxide estimation by a simple and efficient noninvasive technique and its utility as a marker of airway inflammation in mice” J Appl Physiol, vol. 107, pp. 295-301.
[cited by applicant]
Barrett et al. (2007) “NCBI GEO: mining tens of millions of expression profiles—database and tools update” Nucleic Acids Res, vol. 35: pp. D760-D765.
[cited by applicant]
Barshir et al. (2013) “The TissueNet database of human tissue protein-protein interactions” Nucleic Acids Res, vol. 41, pp. D841-D844.
[cited by applicant]
Barshir et al. (2014) “Comparative analysis of human tissue interactomes reveals factors leading to tissue-specific manifestation of hereditary diseases” PLoS Comput Biol, vol. 10, No. 6, Article 1003632 (12 pages).
[cited by applicant]
Baselga el al. (2010) “Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors” Clin Cancer Res, vol. 16, No. 19, pp. 4876-4883.
[cited by applicant]
Bavetsias et al. (2012) “Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatmen…
[cited by applicant]
Bayliss et al. (2012) “On the molecular mechanisms of mitotic kinase activation” Open Biol, vol. 2, Article 120136 (20 pages).
[cited by applicant]
Bhagirath et al. (2016) “Cystic fibrosis lung environment and Pseudomonas aeruginosa infection” BMC Pulm Med, vol. 16, Article 174 (22 pages).
[cited by applicant]
Bjoraker et al. (1998) “Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis” Am J Respir Crit Care Med, vol. 157, pp. 199-203.
[cited by applicant]
Booth et al. (2001) “Interleukin-13 induces proliferation of human airway epithelial cells in vitro via a mechanism mediated by transforming growth factor-alpha” Am J Respir Cell Mol Biol, vol. 25, pp. 739-743.
[cited by applicant]
Boss et al. (2009) “Clinical Experience with Aurora Kinase Inhibitors: A Review” The Oncologist, vol. 14, pp. 780-793.
[cited by applicant]
Boyle et al. (2014) “A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial” Lancet Resp…
[cited by applicant]
Brandvold et al. (2012) “Development of a Highly Selective c-Src Kinase Inhibitor” ACS Chem Biol., vol. 7, No. 8, pp. 1393-1398.
[cited by applicant]
Chapman (2011) “Epithelial-mesenchymal interactions in pulmonary fibrosis” Annu Rev Physiol, vol. 73, pp. 413-435.
[cited by applicant]
Cheng et al. (2014) “Systematic evaluation of connectivity map for disease indications” Genome Med, vol. 6, Article 95 (8 pages).
[cited by applicant]
Chmiel et al. (2013) “Antibiotic and anti-inflammatory therapies for cystic fibrosis” Cold Spring Harb Perspect Med, vol. 3, Article a009779 (17 pages).
[cited by applicant]
Cholon et al. (2014) “Potentiator ivacaftor abrogates pharmacological correction of DeltaF508 CFTR in cystic fibrosis” Sci Transl Med, vol. 6, No. 246, pp. 246ra96 (31 pages).
[cited by applicant]
Clancy (2014) “CFTR potentiators: not an open and shut case” Sci Transl Med, vol. 6, No. 246, Article 246fs27 (3 pages).
[cited by applicant]
Clancy et al. (2013) “Multicenter intestinal current measurements in rectal biopsies from CF and non-CF subjects to monitor CFTR function” PloS One, vol. 8, No. 9, Article e73905 (13 pages).
[cited by applicant]
Cool et al. (2006) “Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum” Am J Respir Crit Care Med, vol. 174, pp. 654-658.
[cited by applicant]
Copiz et al. (2016) “c- Src and its role in cystic fibrosis” Eur J Cell Biol, vol. 95, pp. 401-413.
[cited by applicant]
Dalton et al. (2012) “New model of cystic fibrosis transmembrane conductance regulator proposes active channel-like conformation” J Chem Inf Model, vol. 52, pp. 1842-1853.
[cited by applicant]